Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Shabbir Rangwala"'
1
Akademický článek
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
Autor: Zarir F. Udwadia, Pawan Singh, Hanmant Barkate, Saiprasad Patil, Shabbir Rangwala, Amol Pendse, Jatin Kadam, Wen Wu, Cynthia F. Caracta, Monika Tandon
Publikováno v: International Journal of Infectious Diseases, Vol 103, Iss , Pp 62-71 (2021)
Objective: To assess the efficacy and safety of favipiravir in adults with mild-to-moderate coronavirus disease 2019 (COVID-19). Methods: In this randomized, open-label, parallel-arm, multicenter, phase 3 trial, adults (18–75 years) with RT-PCR con
Externí odkaz: https://doaj.org/article/4e4066fdaf884deba2ec80352ad2f675
Zobrazit plný text záznamu
2
Akademický článek
Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial
Autor: Sundeep Salvi, Akash Balki, Srikanth Krishnamurthy, Sagar Panchal, Saiprasad Patil, Rahul Kodgule, Hitesh Khandagale, Amol Pendse, Wen Wu, Shabbir Rangwala, Monika Tandon, Hanmant Barkate
Publikováno v: ERJ Open Research, Vol 7, Iss 3 (2021)
Background The aim of this work was to investigate the safety and efficacy of single-inhaler triple therapy with 12.5 μg glycopyrronium (GB)/12 μg formoterol fumarate (FF)/250 μg fluticasone propionate (FP), compared to 50 μg GB co-administered w
Externí odkaz: https://doaj.org/article/75c81963141e4675813d77edae65dde4
Zobrazit plný text záznamu
6
Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial
Autor: Saiprasad Patil, Hanmant Barkate, Shabbir Rangwala, Srikanth Krishnamurthy, Sagar Panchal, Amol Pendse, Wen Wu, Monika Tandon, Rahul Kodgule, Hitesh Khandagale, Akash Balki, Sundeep Salvi
Publikováno v: ERJ Open Research, Vol 7, Iss 3 (2021)
ERJ Open Research
article-version (VoR) Version of Record
Background The aim of this work was to investigate the safety and efficacy of single-inhaler triple therapy with 12.5 μg glycopyrronium (GB)/12 μg formoterol fumarate (FF)/250 μg fluticasone propionate (FP), compared to 50 μg GB co-administered w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44612416c93b415845064f16638f3465
http://openres.ersjournals.com/content/7/3/00255-2021.full
Zobrazit plný text záznamu
7
Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial
Autor: Shabbir Rangwala, Hanmant Barkate, Pawan Singh, Jatin Kadam, Zarir F. Udwadia, Amol Pendse, Cynthia F. Caracta, Wen Wu, Monika Tandon, Saiprasad Patil
Publikováno v: International Journal of Infectious Diseases
International Journal of Infectious Diseases, Vol 103, Iss, Pp 62-71 (2021)
Highlights • Favipiravir is an oral RNA-dependent RNA polymerase inhibitor. • Favipiravir is under investigation in many countries for treatment of COVID-19. • We evaluated favipiravir’s efficacy and safety in mild-to-moderate COVID-19. • F
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7853c0f3b810cae39a30815cf5cc6d07
http://europepmc.org/articles/PMC7668212
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje